Key Takeaway
The GLP-1 pipeline of new drugs is packed. This GLP-1 pipeline new drugs resource covers the essential information you need to make informed decisions. Over the next two to three years, a wave of next-generation weight management medications could reach the market.
The GLP-1 pipeline of new drugs is packed. This GLP-1 pipeline new drugs resource covers the essential information you need to make informed decisions. Over the next two to three years, a wave of next-generation weight management medications could reach the market. Each one aims to improve on what semaglutide and tirzepatide have already delivered. More weight loss, fewer side effects, more convenient dosing, and new mechanisms of action are all on the table.
Key Takeaways: - Survodutide: Boehringer Ingelheim's Dual Agonist - CagriSema: Novo Nordisk's GLP-1 + Amylin Combo - Pemvidutide and Amycretin: Other Contenders - Orforglipron and Oral Options - Understand what this means for you today
Here is a breakdown of every major contender, where they stand in clinical trials, and when they might become available.
Survodutide: Boehringer Ingelheim's Dual Agonist
Survodutide targets both GLP-1 and glucagon receptors. Unlike tirzepatide, which pairs GLP-1 with GIP, survodutide pairs GLP-1 with glucagon. The glucagon component may increase energy expenditure and promote liver fat reduction.
Phase 2 trial results were strong. Participants lost an average of about 19% of their body weight over 46 weeks. That puts survodutide between tirzepatide and retatrutide in terms of efficacy.
The liver health angle is particularly interesting. Survodutide showed significant improvement in fatty liver disease markers. Phase 3 trials are specifically studying its use for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
"What makes tirzepatide particularly interesting is the dual GIP/GLP-1 mechanism. We're seeing that GIP receptor activation appears to amplify the metabolic effects in ways we didn't fully anticipate from the preclinical data.") Dr. Ania Jastreboff, MD, PhD, Yale School of Medicine, lead author of SURMOUNT-1
Phase 3 trials for both weight management and liver disease are underway. If successful, survodutide could reach the market by late 2027 or 2028.
For more on current GLP-1 options, see our .
CagriSema: Novo Nordisk's GLP-1 + Amylin Combo
CagriSema combines semaglutide with cagrilintide, a long-acting amylin analog. Amylin is a hormone your pancreas releases alongside insulin after eating. It slows gastric emptying and promotes satiety through different pathways than GLP-1.
Free Download: GLP-1 Medication Comparison One-Pager Track every drug in the GLP-1 pipeline with expected launch dates and trial results. Get yours free (we'll email it to you instantly. [Email Input] [Download Button]
The Phase 3 trial results showed approximately 22-25% body weight loss. By combining two appetite-suppressing hormones through different mechanisms, CagriSema may offer the strongest weight loss numbers of any Novo Nordisk product.
CagriSema is given as a once-weekly injection. Novo Nordisk has submitted regulatory filings, and approval could come as early as late 2026 or early 2027.
This is one of the drugs closest to market. If you are weighing your options, our covers another dual-mechanism option available through compounding pharmacies today.
Pemvidutide and Amycretin: Other Contenders
Pemvidutide from Altimmune is a GLP-1/glucagon dual agonist similar to survodutide. Phase 2 data showed about 15.6% weight loss over 48 weeks. While not as high as some competitors, pemvidutide showed strong improvements in liver fat and cardiovascular markers. Phase 3 trials are underway.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Amycretin from Novo Nordisk is particularly exciting. It combines GLP-1 and amylin activity in a single molecule rather than mixing two separate drugs. Early-phase data suggested up to 13% weight loss in just 12 weeks, which projects to potentially very high weight loss over a full year. However, this data is very early-stage and needs to be confirmed in larger trials.
Orforglipron and Oral Options
The oral GLP-1 space is another important part of the pipeline. Orforglipron from Eli Lilly is a small molecule oral GLP-1 that does not require fasting. Phase 2 results showed about 14.7% weight loss. Phase 3 trials are ongoing, with potential availability in late 2026 or 2027.
Higher-dose oral semaglutide (25 mg and 50 mg tablets) from Novo Nordisk has also shown promising data, with weight loss approaching what injectable semaglutide delivers. These higher doses are under regulatory review.
The oral options could dramatically expand access to GLP-1 treatment by removing the injection barrier for people who are needle-averse.
What This Means for You Today
Here is the reality. The pipeline is exciting, but these drugs are months to years away from your medicine cabinet. Clinical trials can hit delays. FDA reviews take time. Manufacturing scale-up creates bottlenecks. Launch timelines can shift.
What is available right now works well for most people. Compounded semaglutide and tirzepatide are proven medications with strong clinical data. FormBlends connects you with licensed providers who prescribe personalized compounded medications prepared by US-based 503A pharmacies.
You do not need to wait for the perfect drug. The best medication is the one you can start today with proper medical guidance. And as new options become available, your provider can help you evaluate whether switching makes sense for your goals.
For a comparison of currently available options, read our .
Frequently Asked Questions
What is the most effective GLP-1 drug in the pipeline?
Early data suggests retatrutide (triple agonist) and CagriSema (semaglutide + amylin) may produce the highest weight loss, with trials showing 22-25% body weight reduction. However, Phase 3 data is still needed for definitive comparisons.
When will new GLP-1 drugs be available?
CagriSema and orforglipron are closest to market, with potential availability in late 2026 or 2027. Survodutide and retatrutide may follow in 2027-2028. Timelines depend on trial results and FDA review.
Will new GLP-1 drugs be cheaper?
Oral small molecule drugs like orforglipron may be cheaper to manufacture, which could lead to lower prices. However, brand-name pricing depends on many factors beyond manufacturing costs. For affordable GLP-1 options today, see our .
Should I wait for a new GLP-1 drug or start treatment now?
Most providers recommend starting with currently available options rather than waiting. Current GLP-1 medications have strong safety and efficacy data. You can always discuss newer options with your provider as they become available.
How do pipeline GLP-1 drugs differ from current ones?
Pipeline drugs use different strategies to improve results. Some target additional hormone receptors (glucagon, amylin). Others offer oral delivery without fasting requirements. The goal is more weight loss, fewer side effects, and greater convenience.
Ready to Take the Next Step?
Your health goals is personal, and you deserve a plan that fits. FormBlends connects you with licensed providers who can evaluate your needs and create a personalized protocol.
Sources & References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
This content is provided for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare provider with any questions about a medical condition or treatment plan.
Last updated: 2026-03-24